These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32526272)

  • 1. Antibody-dependent enhancement and COVID-19: Moving toward acquittal.
    Yager EJ
    Clin Immunol; 2020 Aug; 217():108496. PubMed ID: 32526272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A plea for the pathogenic role of immune complexes in severe Covid-19.
    Vuitton DA; Vuitton L; Seillès E; Galanaud P
    Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
    [No Abstract]   [Full Text] [Related]  

  • 3. Type 3 hypersensitivity in COVID-19 vasculitis.
    Roncati L; Ligabue G; Fabbiani L; Malagoli C; Gallo G; Lusenti B; Nasillo V; Manenti A; Maiorana A
    Clin Immunol; 2020 Aug; 217():108487. PubMed ID: 32479986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Not just antibodies: B cells and T cells mediate immunity to COVID-19.
    Cox RJ; Brokstad KA
    Nat Rev Immunol; 2020 Oct; 20(10):581-582. PubMed ID: 32839569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
    Xi Y
    Signal Transduct Target Ther; 2020 Sep; 5(1):203. PubMed ID: 32934211
    [No Abstract]   [Full Text] [Related]  

  • 6. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?
    Negro F
    Swiss Med Wkly; 2020 Apr; 150():w20249. PubMed ID: 32298458
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19.
    Luetkens T; Metcalf R; Planelles V; Zheng Y; Larragoite ET; Spivak ES; Spivak AM; Steinbach M; Blaylock RC; Avila SV; Hankey KG; Martins TB; Slev PR; Mannuel HD; Sajadi M; Rapoport AP; Atanackovic D
    Blood Adv; 2020 Oct; 4(19):4864-4868. PubMed ID: 33031540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of atypical memory B cells is a prominent feature of COVID-19.
    Oliviero B; Varchetta S; Mele D; Mantovani S; Cerino A; Perotti CG; Ludovisi S; Mondelli MU
    Cell Mol Immunol; 2020 Oct; 17(10):1101-1103. PubMed ID: 32879471
    [No Abstract]   [Full Text] [Related]  

  • 9. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.
    Morabito CJ; Gangadharan B
    Clin Transl Sci; 2020 Sep; 13(5):835-837. PubMed ID: 32420691
    [No Abstract]   [Full Text] [Related]  

  • 10. Audio Interview: Capitalizing on Immune Responses to Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(21):e93. PubMed ID: 32433859
    [No Abstract]   [Full Text] [Related]  

  • 11. The convalescent sera option for containing COVID-19.
    Casadevall A; Pirofski LA
    J Clin Invest; 2020 Apr; 130(4):1545-1548. PubMed ID: 32167489
    [No Abstract]   [Full Text] [Related]  

  • 12. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
    Arvin AM; Fink K; Schmid MA; Cathcart A; Spreafico R; Havenar-Daughton C; Lanzavecchia A; Corti D; Virgin HW
    Nature; 2020 Aug; 584(7821):353-363. PubMed ID: 32659783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.
    Lee WS; Wheatley AK; Kent SJ; DeKosky BJ
    Nat Microbiol; 2020 Oct; 5(10):1185-1191. PubMed ID: 32908214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The resurgence of convalescent plasma therapy.
    The Lancet Haematology
    Lancet Haematol; 2020 May; 7(5):e353. PubMed ID: 32359447
    [No Abstract]   [Full Text] [Related]  

  • 15. Coronavirus vaccine-associated lung immunopathology-what is the significance?
    Bottazzi ME; Strych U; Hotez PJ; Corry DB
    Microbes Infect; 2020 Oct; 22(9):403-404. PubMed ID: 32599077
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
    Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM
    Clin Immunol; 2020 Oct; 219():108555. PubMed ID: 32771488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.
    Abid MB; Mughal M; Abid MA
    JAMA Oncol; 2020 Oct; 6(10):1529-1530. PubMed ID: 32433719
    [No Abstract]   [Full Text] [Related]  

  • 18. Can Drinking Microfiltered Raw Immune Milk From Cows Immunized Against SARS-CoV-2 Provide Short-Term Protection Against COVID-19?
    Jawhara S
    Front Immunol; 2020; 11():1888. PubMed ID: 32849647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.
    Lu Y; Wang Y; Zhang Z; Huang J; Yao M; Huang G; Ge Y; Zhang P; Huang H; Wang Y; Li H; Wang W
    J Immunol Res; 2020; 2020():9465398. PubMed ID: 33134398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Passive antibody therapy in COVID-19.
    Abraham J
    Nat Rev Immunol; 2020 Jul; 20(7):401-403. PubMed ID: 32533109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.